Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Hosted on MSN
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX)
Fintel reports that on December 17, 2025, JP Morgan upgraded their outlook for Recursion Pharmaceuticals (NasdaqGS:RXRX) from Neutral to Overweight. Analyst Price Forecast Suggests 37.89% Upside As of ...
Many saw desktop impressions drop around Sept. 10. A working theory is that past spikes were inflated by bots loading 100-result pages. Google hasn’t commented yet. Google appears to have disabled the ...
Electron-temperature dependent parameters: electron-phonon coupling (G), electron heat capacity (Ce), and electron heat conductivity (Ke), calculated with XTANT-3 code The electron-ion ...
RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Recursion Pharmaceuticals is known for its Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results